I don't agree but pointless to argue. It all depends as mentioned on different evaluations of peak sales. Generally, BP have higher peak sale internal peak sales capacity than small to mid-pharma due to a lot of the industry is about having long extended relationships with stakeholders, existing channels, and leverage of scale. So when I say 3-5, I mean some of what is being thrown around for peak sales by non institutionals. For AMRN example, I personally believe that BP will depending ond data from AHA view peak sales in the $10B+ range which people are throwing out numbers of 5-6B now. So again, I think BP will pay 3-5 times that as their own internal assessments will be higher. I won't disclose names just look at a few 10ks for the last few years of BP and you will see tons of acqusitions that were premiums that were way worse that were for companies that didnt even have a PHase III results or approved drug. So multiples to buy also go buy liklihood of getting the peak sales, the further you along in the prcess - finished trial that beat results, established approval, existing sales force and actual threat of self commercialization the higher the multiple can go and vice versa. But hey, I'm not making a case for the crazy buy outs peopel are saying. I think 35-75 can be reasonable and maybe higher if there was bidding war.
News 
Market Data 
Discover 
AI
